Antiplatelets are medicines that stop cells in the blood (platelets) from sticking together and forming a clot, which may lead to a heart attack or stroke. Furthermore, the use of antiplatelet after percutaneous coronary intervention is one of the challenge encountered by the clinicians or hospital staff because it has to be calculated between the risk-benefit ratio. This study aims to evaluate the use of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention. A retrospective study was used and data were obtained from patient records. The data obtained were analysed to know the relationship between age, gender, and type of drug combination associated with ischemic events. The patient demographics were ana...
Aspirin and clopidogrel are usually used individually to prevent adverse cardiovascular events and s...
Dual antiplatelet therapy (DAPT) combines two antiplatelet agents to decrease the risk of thrombotic...
BACKGROUND: Current guidelines recommend 6 to 12 months of dual antiplatelet therapy (DAPT) after pe...
Antiplatelet is the most commonly drug used as secondary prevention for Coronary Heart Disease (CHD...
Introduction- Coronary artery disease is one of the most common amongst the heart diseases. It occur...
ObjectivesCHARISMA was a landmark randomized clinical trial that failed to demonstrate a benefit of ...
Objective: Antiplatelet therapy is recommended in patients with coronary heart disease (CHD) who had...
Recent clinical data show that the risk of coronary thrombosis after antiplatelet drugs withdrawal i...
Recent clinical data show that the risk of coronary thrombosis after antiplatelet drugs withdrawal i...
Recent clinical data show that the risk of coronary thrombosis after antiplatelet drugs withdrawal i...
Dual antiplatelet therapy (DAT) has become standard care for patients undergoing percutaneous corona...
Background: This study is to determine the clinical profile of Acute Coronary Syndrome (ACS) patient...
Dual antiplatelet therapy (DAT) has become standard care for patients undergoing percutaneous corona...
Coronary artery bypass grafting is pivotal in the contemporary management of complex coronary artery...
Dual antiplatelet therapy (DAT) has become standard care for patients undergoing percutaneous corona...
Aspirin and clopidogrel are usually used individually to prevent adverse cardiovascular events and s...
Dual antiplatelet therapy (DAPT) combines two antiplatelet agents to decrease the risk of thrombotic...
BACKGROUND: Current guidelines recommend 6 to 12 months of dual antiplatelet therapy (DAPT) after pe...
Antiplatelet is the most commonly drug used as secondary prevention for Coronary Heart Disease (CHD...
Introduction- Coronary artery disease is one of the most common amongst the heart diseases. It occur...
ObjectivesCHARISMA was a landmark randomized clinical trial that failed to demonstrate a benefit of ...
Objective: Antiplatelet therapy is recommended in patients with coronary heart disease (CHD) who had...
Recent clinical data show that the risk of coronary thrombosis after antiplatelet drugs withdrawal i...
Recent clinical data show that the risk of coronary thrombosis after antiplatelet drugs withdrawal i...
Recent clinical data show that the risk of coronary thrombosis after antiplatelet drugs withdrawal i...
Dual antiplatelet therapy (DAT) has become standard care for patients undergoing percutaneous corona...
Background: This study is to determine the clinical profile of Acute Coronary Syndrome (ACS) patient...
Dual antiplatelet therapy (DAT) has become standard care for patients undergoing percutaneous corona...
Coronary artery bypass grafting is pivotal in the contemporary management of complex coronary artery...
Dual antiplatelet therapy (DAT) has become standard care for patients undergoing percutaneous corona...
Aspirin and clopidogrel are usually used individually to prevent adverse cardiovascular events and s...
Dual antiplatelet therapy (DAPT) combines two antiplatelet agents to decrease the risk of thrombotic...
BACKGROUND: Current guidelines recommend 6 to 12 months of dual antiplatelet therapy (DAPT) after pe...